SINOVAC, HKU-CTC & GHK partner for Omicron-specific vaccine trials
Category: #health  By Mateen Dalal  Date: 2022-07-05
  • share
  • Twitter
  • Facebook
  • LinkedIn

SINOVAC, HKU-CTC & GHK partner for Omicron-specific vaccine trials

The Gleneagles Hospital Hong Kong (GHK or Gleneagles) recently held an event to introduce a clinical trial for assessing the security and immunogenicity of Omicron-targeted COVID-19 inactivated vaccine developed by SINOVAC which will be used as a booster shot in adults, in anticipation of offering scientific proof for future immunization strategy.

Credible sources cite that the study is headed by the University of Hong Kong Clinical Trials Centre's (HKU-CTC) medical research team in association with Gleneagles.

A total of 300 adult volunteers aged 18 or above, who have been jabbed with two or three doses of mRNA COVID-19 or inactivated vaccine, will be recruited in this study.

Prof. Ivan Hung Fan-Ngai, a Clinical Prof. at the Department of Medicine and Asst. Dean (Clinical Curriculum & Assessment) at the LKS Faculty of Medicine at the HKUMed (University of Hong Kong) stated during the event that everyone around the world knows that vaccination is one of the most efficient ways to handle infectious diseases.

He further said that at present, Omicron is continuously spreading across the world. Based on this, the clinical trial is expected to effectively enhance and promote vaccine research and vaccination administration.

In December 2021, SINOVAC obtained the Omicron variant's sample and then actively promoted the research and development of its inactivated COVID-19 vaccine.

As per preclinical research, the vaccine is effective and has been found safe in animals.

Following this, the booster immunization clinical trial for Omicron was then approved by the HKU GHK IRB (Institutional Review Board) on April 2022 and by the Pharmacy and Poisons Board of Hong Kong, empowering them to carry out the clinical study for augmenting the immunity of people against the new variant of COVID-19 in Hong Kong.

Source Credit - https://www.businesswire.com/news/home/20220704005146/en/SINOVAC-joins-hands-with-HKU-CTC-research-team-and-Gleneagles-Hospital-Hong-Kong-to-kick-off-a-clinical-trial-of-an-Omicron-specific-inactivated-vaccine-for-booster-use-in-Hong-Kong-China

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...